NECTIN4 expression in sebaceous and sweat gland carcinoma

Ito, Takamichi; Hashimoto, H.; Tanaka, Yuka; Tanegashima, Keiko; Murata, Maho; Oda, Yoshinao; Kaku-Ito, Yumiko

doi:10.1684/ejd.2022.4241

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FDA-approved ADCs for solid tumors include trastuzumab emtansine and trastuzumab deruxtecan (anti-HER2 ADCs) for breast cancer, enfortumab vedotin (anti-NECTIN-4 ADC) for urothelial cancer, sacituzumab govitecan (anti-TROP-2 ADC) for breast cancer, and tisotumab vedotin (anti-tissue factor ADC) for cervical cancer. Interestingly, NECTIN-4 and TROP-2 are highly expressed in normal skin and its appendages, as well as in various skin cancers [ 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 ], and anti-NECTIN-4 ADC might be a candidate for unresectable skin cancers, including NAM. Several melanoma-specific ADCs are currently undergoing preclinical and clinical trials.…”

Section: Treatmentmentioning

confidence: 99%

Nail Apparatus Melanoma: Current Management and Future Perspectives

Ito

Hashimoto

Kaku-Ito

et al. 2023

JCM

View full text Add to dashboard Cite

Nail apparatus melanoma (NAM) is a rare type of cutaneous melanoma that belongs to the acral melanoma subtype. NAM is managed principally in accordance with the general treatment for cutaneous melanoma, but there is scarce evidence in support of this in the literature. Acral melanoma is genetically different from non-acral cutaneous melanoma, while recently accumulated data suggest that NAM also has a different genetic background from acral melanoma. In this review, we focus on recent advances in the management of NAM. Localized NAM should be surgically removed; amputation of the digit and digit-preserving surgery have been reported. Sentinel lymph node biopsy can be considered for invasive NAM for the purpose of accurate staging. However, it is yet to be clarified whether patients with metastatic sentinel lymph nodes can be safely spared completion lymph node dissection. Similar to cutaneous melanoma, immune checkpoint inhibitors and BRAF/MEK inhibitors are used as the first-line treatment for metastatic NAM, but data on the efficacy of these therapies remain scarce. The therapeutic effects of immune checkpoint inhibitors could be lower for NAM than for cutaneous melanoma. This review highlights the urgent need to accumulate data to better define the optimal management of this rare melanoma.

show abstract

Section: Treatmentmentioning

confidence: 99%

Nail Apparatus Melanoma: Current Management and Future Perspectives

Ito

Hashimoto

Kaku-Ito

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

KS-EMPD-1: a novel cell line of primary extramammary Paget’s disease

et al. 2023

View full text Add to dashboard Cite

Nectin‐4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin

Cho,

Saade,

Nagarajan

et al. 2024

J Cutan Pathol

View full text Add to dashboard Cite

BackgroundEnfortumab vedotin (EV) is an antibody‐drug conjugate directed against Nectin‐4 that is used to treat urothelial carcinoma. Nectin‐4 is inherently expressed in the skin and adnexal structures. Since therapeutic options for cutaneous adnexal carcinomas are limited, we sought to evaluate Nectin‐4 expression in adnexal carcinomas and benign adnexal neoplasms to identify tumors that are potentially targetable with EV.MethodsEight sebaceous carcinomas (seven periocular and one lymph node metastasis), eight digital papillary adenocarcinomas, seven squamoid eccrine ductal carcinomas, eight poromas, eight trichilemmomas, and seven sebaceous adenomas were subjected to immunohistochemical staining for anti‐Nectin‐4 antibody. H‐scores for Nectin‐4 expression were calculated.ResultsBenign adnexal neoplasms had a significantly lower mean (±SD) Nectin‐4 H‐score (142.6 ± 39.1) than did the adnexal carcinomas (198 ± 90.8; p = 0.006). Nectin‐4 was expressed in 91% (21/23) of adnexal carcinomas. Sebaceous carcinomas frequently exhibited high expression of Nectin‐4 (88% [7/8]), with a mean (±SD) H‐score (258.1 ± 58.4) significantly higher than those for digital papillary adenocarcinomas (197.5 ± 52.5; p = 0.035) and squamoid eccrine ductal carcinomas (131.4 ± 114.1; p = 0.031). Sebaceous carcinomas also had significantly higher H‐scores than did sebaceous adenomas (186.4 ± 25.0; p = 0.013).ConclusionsIncreased Nectin‐4 expression in a subset of cutaneous adnexal carcinomas, particularly sebaceous carcinomas, reveals that EV is a potential therapeutic option for these tumors.

show abstract

NECTIN4 expression in sebaceous and sweat gland carcinoma

Cited by 5 publications

References 0 publications

Nail Apparatus Melanoma: Current Management and Future Perspectives

Nail Apparatus Melanoma: Current Management and Future Perspectives

KS-EMPD-1: a novel cell line of primary extramammary Paget’s disease

Nectin‐4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin

Contact Info

Product

Resources

About